Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Progressive Corp (PGR) Price & Performance

Novo Nordisk A/STrade
Progressive CorpTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Progressive Corp — how do they compare? Novo Nordisk A/S trades at $46.23 (market cap $207.85B), while Progressive Corp trades at $209.28 (market cap $123.45B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Progressive Corp pays the higher dividend (6.55%). Which is the better fit depends on your goals.

NVOPGR
Market Cap
$207.85B$123.45B
Sector
HealthFinancials
52-Week High
$63.98$252.68
52-Week Low
$35.29$190.40
Enterprise Value
$222.55B$131.66B
Dividend Yield
3.81%6.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.

The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.

Progressive Corp

Progressive (PGR) trades at $213.95, down 0.64% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamental performance with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Recent Q2 2026 earnings beat expectations at $4.85 per share, though the combined ratio widened to 87.1%, indicating potential growth trade-offs. Analyst consensus price target stands at $231.20 with 37% buy ratings.

PGR presents a compelling investment case with reasonable valuation (P/E 10.65) and strong profitability (ROE 34.94%), though investors face risks from competitive pressures and potential margin compression as the company expands its bundled insurance offerings. The stock offers 8% upside to consensus target with balanced risk-reward profile.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About Progressive Corp

Progressive underwrites private and commercial auto insurance and specialty lines

Read more on PGR